Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 22 citing articles:

SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity
Stefan Pilz, Verena Theiler‐Schwetz, Christian Trummer, et al.
Environmental Research (2022) Vol. 209, pp. 112911-112911
Open Access | Times Cited: 235
Drug Repurposing in Oncology: A Systematic Review of Randomized Controlled Clinical Trials
Ignatios Ioakeim‐Skoufa, Natalia Tobajas-Ramos, Enrica Menditto, et al.
Cancers (2023) Vol. 15, Iss. 11, pp. 2972-2972
Open Access | Times Cited: 14
SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy
Desh Deepak Singh, Anshul Sharma, Hae‐Jeung Lee, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 20
Emerging small molecule antivirals may fit neatly into COVID-19 treatment
Caroline Fenton, Susan J. Keam
Drugs & Therapy Perspectives (2022) Vol. 38, Iss. 3, pp. 112-126
Open Access | Times Cited: 20
Benefits of probiotic use on COVID-19: A systematic review and meta-analysis
Suelen Neris Almeida Viana, Tamires do Reis Santos Pereira, Janaína de Carvalho Alves, et al.
Critical Reviews in Food Science and Nutrition (2022) Vol. 64, Iss. 10, pp. 2986-2998
Closed Access | Times Cited: 13
Small-molecule antiviral treatments for COVID-19: A systematic review and network meta-analysis
Bei Zheng, Qinqin Zhao, Wenjuan Yang, et al.
International Journal of Antimicrobial Agents (2024) Vol. 63, Iss. 3, pp. 107096-107096
Open Access | Times Cited: 2
Comparative efficacy and safety of pharmacological interventions for severe COVID-19 patients: An updated network meta-analysis of 48 randomized controlled trials
Qinglin Cheng, Gang Zhao, Chen Jun-fang, et al.
Medicine (2022) Vol. 101, Iss. 41, pp. e30998-e30998
Open Access | Times Cited: 9
Efficacy and safety of current treatment interventions for patients with severe COVID‐19 infection: A network meta‐analysis of randomized controlled trials
Qinglin Cheng, Gang Zhao, Chen Jun-fang, et al.
Journal of Medical Virology (2021) Vol. 94, Iss. 4, pp. 1617-1626
Open Access | Times Cited: 12
Meta-Analyses Do Not Establish Improved Mortality With Ivermectin Use in COVID-19
Steven G. Rothrock, Kurt Weber, Philip Giordano, et al.
American Journal of Therapeutics (2021) Vol. 29, Iss. 1, pp. e87-e94
Open Access | Times Cited: 11
Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19)
Matthew W. McCarthy
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 5, pp. 623-628
Open Access | Times Cited: 7
Efficacy of umbilical cord mesenchymal stromal cells for COVID-19: A systematic review and meta-analysis
Cong-wen Yang, Rudong Chen, Qing-run Zhu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 7
Ofeleein i mi Vlaptin—Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic
Jannis Kountouras, Dimitra Gialamprinou, Georgios Kotronis, et al.
Medicina (2022) Vol. 58, Iss. 2, pp. 309-309
Open Access | Times Cited: 6
SARS-CoV-2 Reinfections: Overview of Efficacy and Duration of Natural and Hybrid Immunity
Stefan Pilz, Verena Theiler‐Schwetz, Christian Trummer, et al.
SSRN Electronic Journal (2022)
Closed Access | Times Cited: 5
Death and invasive mechanical ventilation risk in hospitalized COVID-19 patients treated with anti-SARS-CoV-2 monoclonal antibodies and/or antiviral agents: A systematic review and network meta-analysis protocol
Sumanta Saha
PLoS ONE (2022) Vol. 17, Iss. 6, pp. e0270196-e0270196
Open Access | Times Cited: 5
Intravenous immunoglobulin for treatment of hospitalized COVID-19 patients: an evidence mapping and meta-analysis
Meixuan Li, Yan-fei Li, Xin Xing, et al.
Inflammopharmacology (2023) Vol. 32, Iss. 1, pp. 335-354
Closed Access | Times Cited: 2
Safety of anti-COVID treatments on the cardiovascular system
Rajan Singh Sondh, Maariyah Vankad, Priyanshu Saha, et al.
Elsevier eBooks (2024), pp. 207-221
Closed Access
Evaluating imatinib in severe COVID-19: a systematic review and meta-analysis
João Pedro Sarcinelli Chagas, Juliana Ribeiro de Oliveira, Vinicius Andreata Brandão, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene (2024)
Closed Access
Oral anti-COVID-19 drugs that were recently evaluated by FDA or EMA: a review
Dorota Lorenz, Rafał Pawliczak
Alergologia Polska - Polish Journal of Allergology (2022) Vol. 9, Iss. 1, pp. 33-40
Open Access | Times Cited: 2
Sotrovimab: Neutralizing Antibody to Combat COVID-19
Aya Allam, Steven Lippmann
The University of Louisville Journal of Respiratory Infections (2022) Vol. 6, Iss. 1
Open Access | Times Cited: 1
IVERMECTINA: De la claridad del amanecer a las tinieblas de la noche
Judith González‐Christen
Quimiofilia (2023) Vol. 1, Iss. 1, pp. 13-16
Open Access
Supplementation with Vitamin D, Zinc, and Quercetin to Treat COVID-19: A Case Report
Brett Martin
(2023)
Open Access
Efficacy and Safety of Ixekizumab vs. Low-Dose IL-2 vs. Colchicine <i>vs.</i> Standard of Care on the Treatment of Patients Hospitalized with Moderate to Critical Covid-19: A Pilot Randomized Clinical Trial (STRUCK: <u>S</u>urvival <u>T</u>rial <u>U</u>sing <u>C</u>yto <u>k</u>ine Inhibitors)
Lívia Pimenta Bonifácio, Eduardo Ramacciotti, Leandro Barile Agati, et al.
SSRN Electronic Journal (2022)
Closed Access
Page 1

Scroll to top